Serina Therapeutics, Inc.

SER NYSE SEC CIK 1708599
Follow Serina Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $125K
Net income −$7.9M −72.4% vs same quarter last year
EPS, diluted −$0.31 +31.1% vs same quarter last year
Operating cash flow −$5.5M −42.7% vs same quarter last year
Revenue by quarter
$0
$130K
$0
$130K
$0
$125K
Q1 25 Q2 25 Q3 25 Q4 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$20M−$10M$0$10MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$130K−$19.2M
FY24$56K−$11.1M
FY23$3.2M$5.3M
FY22$34K−$10.5M
FY21$144K−$8.7M
FY20$361K−$10.9M
FY19$1.7M−$12.2M
FY18$1.4M−$7.5M
FY17$1.4M−$6.6M
FY16--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−40000%−30000%−20000%−10000%0%10000%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25-−18478.5%−14755.4%
FY24-−30442.9%−19894.6%
FY233.2%−99.2%167.1%
FY2261.8%−20514.7%−30770.6%
FY2186.8%−5509%−6024.3%
FY2092.8%−2797.8%−3009.7%
FY1985.9%−726.8%−703.4%
FY1873.9%−805.5%−537.4%
FY1788%−474.6%−468.7%
FY16---
Free cash flowOperating cash flow minus capital expenditure
−$20M−$15M−$10M−$5M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$18M
FY24−$17.2M
FY23−$3M
FY22-
FY21-
FY20−$7.8M
FY19−$10.8M
FY18−$8M
FY17−$6.3M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Serina Therapeutics
  • Healthcare median
−40000%−30000%−20000%−10000%0%10000%FY17FY19FY21FY23FY25
Show the numbers
YearSerina TherapeuticsHealthcare median
FY25−14755.4%−30.6%
FY24−19894.6%−47%
FY23167.1%−58%
FY22−30770.6%−80.4%
FY21−6024.3%−71.9%
FY20−3009.7%−62.2%
FY19−703.4%−46.3%
FY18−537.4%−49.6%
FY17−468.7%−45.9%
FY16-−36%